FDA asks for advice on risk communications

Share this article:
Taking its lead from the IOM report, the FDA is establishing an advisory committee on risk communications. The committee will focus primarily on communications to the public, though it may also look at communication with physicians, said Crystal Rice of CDER media relations. It will consist of patient and consumer representatives, as well as people with expertise in risk communication, social marketing, health literacy and the social sciences generally. The agency aims to empanel the committee quickly, said Rice, and while not permanent, it will probably be a long-term endeavor. “Given the continuing importance of effective communication about regulated products, our initial thoughts are that this committee will continue to be useful over time,” said Rice. Other steps to improve drug safety announced by the agency include: a pilot program to assess the utility of postmarketing evaluation for routine new molecular entities; organizational and management changes to tighten communications between review and safety staff; more information sharing between FDA and the Veterans Health Administration; a CDER electronic safety tracking system; and an upgrade of the Adverse Events Reporting System database with new signal detection and tracking tools.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...